Crizanlizumab-tmca (Adakveo)

Adakveo (crizanlizumab‑tmca) is covered to reduce vaso‑occlusive crises in sickle cell patients aged ≥16 who had ≥1 sickle cell–related crisis in the prior 12 months and is not covered for non‑FDA indications or for patients who don’t meet the age, crisis, or hydroxyurea criteria. Authorization requires SCD specialist prescribing/consultation, documentation of diagnosis/age/crisis and hydroxyurea status, dosing 5 mg/kg IV (week 0, week 2, then ≥every 4 weeks), approvals for 12 months, and re‑authorization only with documented clinical benefit.

"Adakveo is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease."

Sign up to see full coverage criteria, indications, and limitations.